Intermediate compound for synthesizing pharmaceutical agent and production method thereof
Abstract
The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invention also relates to a production method of an compound represented by the formula 55, which includes the following steps: wherein each symbol is as defined in the specification. According to the production method of the present invention, an optically active 2-aryl-substituted morpholine compound and 3-oxo-3-(pyrimidin-4-yl)propionate, which are important as starting materials for synthesizing 2-(2-arylmorpholin-4-yl)-1-methyl-1H-[4,4′]bipyrimidinyl-6-one having a tau protein kinase 1 inhibitory activity and useful as a therapeutic drug for Alzheimer's disease and the like, can be produced in a high yield by an industrially advantageous method.
Claims
exact text as granted — not AI-modified1 . A production method of an optically active compound represented by the formula (I),
wherein R is an aryl optionally having substituent(s) or a heteroaryl optionally having substituent(s), and a carbon atom marked with * is an asymmetric carbon atom; which comprises:
synthesizing a compound represented by the formula 55, which comprises the following steps:
wherein R a and R b are the same or different and each is a C 1-6 alkyl,
reacting orotic acid of the formula 51 with an alkylating agent in a solvent in the presence of a base to give a compound of the formula 52,
heating the compound of the formula 52 under reflux with a chlorinating agent to give a compound of formula 53,
dechlorinating the compound of the formula 53 in the presence of a base to give a compound of the formula 54, and
reacting the compound of the formula 54 with acetate in the presence of a base to give the compound of the formula 55.Join the waitlist — get patent alerts
Track US2011251385A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.